Abstract:Pleomorphic adenoma is the most common benign tumor of the salivary glands tumors. First line treatment for this tumor is surgical excision and adjuvant radiotherapy was reported being applied to recurrent pleomorphic adenoma with high risk of recurrence. The aim of this study was to discuss the safety and treatment efficacy of (125) I seed interstitial brachytherapy for recurrent pleomorphic adenoma and propose the method to solve the clinical difficulty. Patients with recurrent pleomorphic adenoma of head and neck were included if the tumor cannot achieve complete resection with high risk of facial paralysis or high incidence of recurrence after operation. Patients were excluded if the tumor can achieve completely resection, risk and quality of life after surgery can be accepted, the patient had other malignant tumor history or were medically inoperable. The patients were performed CT and MRI used to develop the (125) I brachytherapy Plan in brachytherapy treatment planning system. The planning target volume (PTV) margin was designed matching the tumor margin. With 3D printing Individual template, CT or surgical navigation system guidance (125) I seed implantation was performed. Post-operation CT used to develop quality verification. The matched peripheral dose (MPD) was ranging from 110 to 140Gy. CT, MRI and biopsy were applied to evaluate treatment efficacy. From June 2012 to October 2015, 12 patients with recurrent pleomorphic adenoma were treated with (125) I seed brachytherapy alone (12 patients) or combined with surgery (1 patients), with follow-up ranging from 6 to 40 months (median, 15 months). Primary site of 13 patients was all parotid gland. Recurrent site of 8 patients were parotid gland while 3 were buccal and 2 were skull base. Patients accepted previous surgery from 1 to 4 times (median, 2.6 times) and 9 of 13 patients presented multinodular recurrence. 6 patients (50%) with 140Gy MPD reached complete response and 6 patients (50%) with 110∼120Gy MPD reached partial response in the 12 brachytherapy alone patients. The 6 patients also reached complete response 6 months after receiving the second time brachytherapy while nodules less than 1cm were all regression after the first time brachytherapy. 1 patient with adjuvant brachytherapy was no sign of tumor. 13 patients were locally controlled and facial nerve function was all preserved. No severe toxicities were observed. Preliminary results of this study showed 125I seed interstitial brachytherapy for recurrent pleomorphic adenoma presented excellent treatment efficacy which provided a safe and minimally invasive method avoiding the risk of facial paralysis brought by reoperation. Planning target volume and prescription dose could be optimized based on clinical and pathological features of recurrent pleomorphic adenoma and the size of tumor. Radiobiology and dosimetry problems about low-dose-rate brachytherapy for recurrent pleomorphic adenoma need further research.

125I Interstitial Brachytherapy for the Treatment of Myoepithelial Carcinoma of the Oral and Maxillofacial Region

Effects Of Radioactive Iodine-125 Seed Implantation On Therapeutic Efficacy, Serum Vegf, Cea Levels, And Prognosis Of Patients With Ocular Malignant Tumors

125 I Seed Implant Brachytherapy-Assisted Surgery for Treatment of Mucoepidermoid Carcinoma of Parotid

Clinicopathologic Analysis Of Oral Squamous Cell Carcinoma After I-125 Interstitial Brachytherapy

The Role of 125 I Interstitial Brachytherapy for Inoperable Parotid Gland Carcinoma

Clinical effectiveness of 125I-seed implantation in combination with nimotuzumab therapy for the advanced oral carcinoma: preliminary results

Surgery Combined with Postoperative 125i Seed Brachytherapy for the Treatment of Mucoepidermoid Carcinoma of the Parotid Gland in Pediatric Patients

Efficacy Of Combined Surgery And I-125 Seed Brachytherapy For Treatment Of Primary Mucoepidermoid Carcinoma Of The Parotid Gland

(125)I Seed Interstitial Brachytherapy for Recurrent Pleomorphic Adenoma

Preliminary Results of (125)I Interstitial Brachytherapy for Locally Recurrent Parotid Gland Cancer in Previously Irradiated Patients.

Iodine-125 Brachytherapy Alone for Advanced Primary Parotid Gland Carcinoma.

Definitive 125I Brachytherapy of Locally Advanced Adenoid Cystic Carcinoma Involving the Skull Base with Satisfying Efficacy and Safety.

Postoperative Iodine-125 Interstitial Brachytherapy for the Early Stages of Minor Salivary Gland Carcinomas of the Lip and Buccal Mucosa with Positive or Close Margins

Surgery combined with 125I seed implantation brachytherapy for treatment of malignant submandibular gland tumors

Application of 125I interstitial brachytherapy in the treatment of local advanced parotid adenoid cystic carcinoma

Application of radioactive particle interstitial implant brachytherapy in the treatment of malignant adenogenous tumors invaded into cranial base area

Postoperative [I-125] Seed Brachytherapy In The Treatment Of Acinic Cell Carcinoma Of The Parotid Gland With Associated Risk Factors

[125I seed implant brachytherapy of recurrent parotid gland malignant tumor].

125I Brachytherapy Alone for Recurrent or Locally Advanced Adenoid Cystic Carcinoma of the Oral and Maxillofacial Region

[The Technic and Dose Evaluation of Postoperative (125)I Radioactive Seeds Brachytherapy for Malignant Tumors of Maxilla].

Radioactivity Seeds Interstitial Brachtherapy Treating Malignant Salivary Gland Tumors